Beijing Key Laboratory of Pediatric Respiratory Infection diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, Research Unit of Critical Infection in Children, Chinese Academy of Medical Sciences, 2019RU016, Laboratory of Infection and Virology, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Department of Microbiology and Parasitology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.
Appl Microbiol Biotechnol. 2020 Aug;104(15):6779-6789. doi: 10.1007/s00253-020-10710-z. Epub 2020 Jun 15.
Zika virus (ZIKV) and Japanese encephalitis virus (JEV) are closely related to mosquito-borne flaviviruses. Japanese encephalitis (JE) vaccine SA14-14-2 has been in the Chinese national Expanded Program on Immunization since 2007. The recent recognition of severe disease syndromes associated with ZIKV, and the identification of ZIKV from mosquitoes in China, prompts an urgent need to investigate the potential interaction between the two. In this study, we showed that SA14-14-2 is protective against ZIKV infection in mice. JE vaccine SA14-14-2 triggered both Th1 and Th2 cross-reactive immune responses to ZIKV; however, it was cellular immunity that predominantly mediated cross-protection against ZIKV infection. Passive transfer of immune sera did not result in significant cross-protection but did mediate antibody-dependent enhancement in vitro, though this did not have an adverse impact on survival. This study suggests that the SA14-14-2 vaccine can protect against ZIKV through a cross-reactive T cell response. This is vital information in terms of ZIKV prevention or precaution in those ZIKV-affected regions where JEV circulates or SA14-14-2 is in widespread use, and opens a promising avenue to develop a novel bivalent vaccine against both ZIKV and JEV. KEY POINTS: • JEV SA14-14-2 vaccine conferred cross-protection against ZIKV challenge in mice. • T cell immunity rather than antibody mediated the cross-protection. • It provides important information in terms of ZIKV prevention or precaution.
寨卡病毒（ZIKV）和日本脑炎病毒（JEV）是与蚊媒黄病毒密切相关的病毒。自 2007 年以来，日本脑炎（JE）疫苗 SA14-14-2 已纳入中国国家免疫规划。最近认识到寨卡病毒与严重疾病综合征有关，并在中国蚊子中发现了寨卡病毒，这促使人们迫切需要研究两者之间的潜在相互作用。在这项研究中，我们表明 SA14-14-2 可保护小鼠免受 ZIKV 感染。JE 疫苗 SA14-14-2 可引发针对 ZIKV 的 Th1 和 Th2 交叉反应性免疫应答；然而，细胞免疫主要介导对 ZIKV 感染的交叉保护。免疫血清的被动转移并未导致明显的交叉保护，但在体外介导抗体依赖性增强，尽管这对生存没有不利影响。这项研究表明，SA14-14-2 疫苗可以通过交叉反应性 T 细胞反应来预防 ZIKV。对于 ZIKV 流行地区或 JEV 流行地区或广泛使用 SA14-14-2 的地区，预防或预防 ZIKV 的重要信息，为开发针对 ZIKV 和 JEV 的新型双价疫苗开辟了有希望的途径。 关键点： • JEV SA14-14-2 疫苗可在小鼠中预防 ZIKV 挑战。 • T 细胞免疫而不是抗体介导交叉保护。 • 对于预防或预防 ZIKV 具有重要意义。
